|
DESLORELIN
ACETATE
|
|
Tryptal; (D-Trp(6)-pro(9)-NEt)-GNRH;
(D-Trp(6)-pro(9))-LHRH; (D-Trp(6)-pro(9))-luteinizing hormone-releasing;
(D-Trp6,Pro9-NHEt)LH-RH; (D-Trp6,des-Gly-NH210)-LH-RH;
(D-Trp6,des-Gly10)-LH-RH; (Des-Gly10(D-Tro6)-LH-RH;
(de-Gly10,D-Trp6,Pro-NHEt)-LH-RH; Somagard; [des-Gly10,
D-Trp6]-LH-RH; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-
prolinamide; D-Trp LHRH-PEA; D-Trp(sup 6)-pro(sup 9)-N-ethylamide-LHRH;
Deslorelin; Deslorelina; Deslorelina; Desloreline;
Deslorelinum; GNRH (D-Trp6,pro9-net); |
|
|
| PRODUCT
IDENTIFICATION
|
|
CAS
RN
|
82318-06-7 (acetate);
57773-65-6(ethylamide) |
|
EINECS
RN |
|
|
FORMULA |
C64H83N17O12 |
|
MOLE
WEIGHT
|
1282.46 |
|
CHEMICAL
FAMILY
|
Polypeptide |
|
CATEGORIES |
LHRH agonist |
| PHYSICAL
AND CHEMICAL PROPERTIES
|
|
PHYSICAL
STATE |
White to off-white powder |
|
MELTING
POINT |
|
|
BOILING
POINT |
|
|
DENSITY
|
|
|
SOLUBILITY
IN WATER |
Soluble (soluble
in 1% acetic acid) |
|
pH |
|
|
VAPOR
DENSITY |
|
|
REFRACTIVE
INDEX
|
|
|
FLASH
POINT |
|
| STABILITY AND REACTIVITY |
|
STABILITY |
Stable
under normal conditions. |
|
INCOMPATIBLE
MATERIALS
|
Strong
acids, Strong bases
|
|
DECOMPOSITION PRODUCTS |
Carbon
oxides, nitrogen oxides
|
|
POLYMERIZATION |
Has not been reported |
|
NFPA
RATINGS
|
|
| SAFETY
|
|
HAZARD
NOTES |
Toxic,
May impair fertility |
|
EYE
|
May
cause eye irritation.
|
|
SKIN |
May
be harmful if absorbed through skin. May cause skin
irritation.
|
|
INGESTION |
May
be harmful if swallowed.
|
|
INHALATION |
May
be harmful if inhaled. May cause respiratory tract irritation.
|
|
CHRONIC |
|
| TRANSPORT
& REGULATORY INFORMATION
|
|
UN
NO. |
|
| HAZARD CLASS |
|
| PACKING GROUP |
|
| HAZARD SYMBOL
|
T
|
|
RISK PHRASES |
60 |
|
SAFETY PHRASES |
53-22-36/37/39-45
|
| EXTERNAL LINKS
& GENERAL
INFORMATION |
|
Wikipedia
Linking: http://en.wikipedia.org/wiki/Deslorelin
Prostate cancer hormone therapy treatment may use LHRH agonists,
also known as Luteinizing hormone-releasing hormone (LHRH) agonists or
Gonadotropin releasing hormone (GnRH) agonists.
Luteinizing hormone-releasing hormone and Gonadotropin-releasing hormone are
essentially the same chemicals which are released by the hypothalamus when it
detects lowering levels of testosterone. An agonist is a chemical that mimics a naturally-occurring
substance in the body and produces the same physiological effect. The agonist
will occupy the cell receptors of the chemical it is mimicking. An agonist has a
longer biological half-life, meaning the body takes longer to metabolize and
eliminate the agonist. The agonist therefore will occupy a receptor for a longer
period of time. Agonists are sometimes referred to as analogues because they are
inserted beneath the skin where they continuously emit LHRH agonist of GnRH
agonist for a prostate
cancer treatment. LHRH and GnRH agonists are also administered as an
injection that can be performed in a doctor’s office or at home.(http://www.prostate-cancer.com/)
Triptorelin
is a synthetic analogue of gonadorelin
(natural GnRH decapeptide) with amino acid (D-tryptophan) substitution in position 6 to
inhibit rapid degradation for long activity. Used as triptorelin pamoate or
acetate form, triptorelin is used as an antineoplastic
in the palliative treatment of prostatic carcinoma, administered
intramuscularly. Other analogues with two substituents in position 6 and 10
include Buserelin, Deslorelin. Goserelin, Histrelin,
Leuprolide, Nafarelin,
|
GnRH
agonist
|
|
|
Product
|
CAS
RN.
|
|
Deslorelin
|
57773-65-6
|
| Goserelin |
65807-02-5 |
| Leuprolide acetate |
74381-53-6 |
| Leuprolide |
53714-56-0 |
| Histrelin |
76712-82-8 |
| Lutrelin acetate |
83784-18-3 |
| Nafarelin acetate |
86220-42-0 |
| Buserelin |
57982-77-1 |
| Buserelin acetate |
68630-75-1 |
| Triptorelin |
57773-63-4 |
| Nafarelin |
76932-56-4 |
|
GnRH
antagonist
|
|
|
Product
|
CAS
RN.
|
|
Detirelix
|
89662-30-6 |
| Detirelix acetate |
102583-46-0 |
| Abarelix |
183552-38-7 |
| Teverelix |
144743-92-0 |
| Cetrorelix |
120287-85-6 |
| Ganirelix |
124904-93-4 |
| Iturelix |
112568-12-4 |
|
| SALES
SPECIFICATION
|
|
APPEARANCE |
White to off-white powder |
|
IDENTIFICATION |
pass
(HPLC)
|
|
PEPTIDE
CONTENT
|
98.5%
min
|
|
AMINO ACID |
Ser: 0.8 - 1.1 Glx: 0.9 - 1.1 Pro: 0.9 - 1.1 Leu: 0.9 - 1.1 Tyr:
0.9 - 1.1 His: 0.9 - 1.1 Arg: 0.9 - 1.1 Trp: Present |
|
RELATED
SUBSTANCES
|
[D-pGlu1]Deslorelin: 0.5% max
[D-His2]Deslorelin: 0.5% max Ser(Ac)4-Deslorelin: 0.5% max Oher
individual impurity: 0.3% max Total impurity: 1.5% max |
|
PEPTIDE CONTENT |
80.0%
min (N determination)
|
|
ACETIC
ACID |
12.0%
max
|
|
TRIFLUOROACETIC
ACID |
0.3% max |
|
OPTICAL
ROTATION |
-70°
~ -82°(c=0.1, 1% acetic acid) |
|
MICROBIOLOGICAL
TEST
|
Total viable aerobic count:
100 CFU/g max Bacterial endotoxins: 2 IU/mg max |
|
RESIDUAL
SOLVENTS |
0.1%
max |
| PRICE
INFORMATION
|
 |
|